Stoke Therapeutics Stock Price, News & Analysis

Stoke Therapeutics and Biogen (Nasdaq: BIIB) will present new clinical and EEG analyses for zorevunersen at the 2025 American Epilepsy Society Annual Meeting (Dec 5–9, Atlanta).

Presentations report up to four years of data from Phase 1/2a and ongoing open‑label extension (OLE) studies, including propensity‑weighted analyses and EEG findings in patients with Dravet syndrome. Zorevunersen is also being evaluated in the global pivotal Phase 3 EMPEROR study in children and adolescents with Dravet syndrome.

Sessions include one oral presentation (Dec 5) and multiple posters (Dec 6–8) covering seizure outcomes, seizure‑free days, quality of life, overall functioning, and electrophysiological EEG changes linked to seizure reductions.

Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective November 17, 2025 to Naomi Muse, newly appointed Senior Vice President, Program Leadership and Management, and six other new employees.

Key terms: 80,000 options to Ms. Muse and an aggregate of 156,490 options to six employees; exercise price $26.95 per share (closing price on November 17, 2025); options vest over 4 years (25% at one year, then monthly over 36 months); 10-year term; grants subject to the 2023 Inducement Plan and option agreements.

Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 9:00 a.m. ET.

The company is developing zorevunersen, a lead investigational medicine for Dravet syndrome that aims to restore protein expression using RNA medicine. A live webcast and archived replay of the presentation will be available in the Investors & News section of Stoke's website.

Stoke Therapeutics (NASDAQ: STOK) reported Q3 2025 results and program updates on November 4, 2025. Key facts: $328.6M cash and marketable securities as of Sept 30, 2025, expected to fund operations to mid‑2028. Q3 revenue was $10.6M (Q3 2024: $4.9M); nine‑month revenue was $183.0M driven largely by a $150.8M IP license performance obligation. Q3 net loss was $38.3M (−$0.65/share); YTD net income was $51.0M (+$0.85/share).

Clinical: Phase 3 EMPEROR active in US/UK/Japan with >20 randomized and ~35 in screening; enrollment expected complete in H2 2026. FDA meeting under Breakthrough Therapy Designation planned before year‑end 2025. STK‑002 Phase 1 recruitment underway in the UK.

Stoke Therapeutics (Nasdaq: STOK) will host a webcast and conference call on Tuesday, November 4, 2025 at 4:30 p.m. ET to discuss third quarter 2025 business and financial updates. Management will present remarks followed by a Q&A for analysts and investors.

Research analysts planning to participate may register to receive dial-in details and a unique PIN; all others can access the listen-only webcast via the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. An archived replay will be available for at least 90 days after the event.

Stoke Therapeutics (NASDAQ: STOK) presented two-year results from the FALCON prospective natural history study in Autosomal Dominant Optic Atrophy (ADOA) (n=47) at AAO on October 18, 2025. Key findings: 24% of patients experienced ≥5-letter loss in low-contrast visual acuity (LCVA); participants showed higher mitochondrial dysfunction versus healthy controls; no significant anatomic retinal changes were observed. Results informed the company’s Phase 1 OSPREY study evaluating the antisense oligonucleotide STK-002 as a potential disease-modifying therapy for OPA1-associated ADOA.

Stoke Therapeutics (Nasdaq: STOK) granted stock options as inducement awards effective October 15, 2025 to ten new employees totaling 195,800 shares. The options carry an exercise price of $35.60 per share, stated as equal to the closing price on September 15, 2025.

Each option vests over a 4-year schedule (25% after one year, then monthly vesting over 36 months), is subject to continued employment, has a 10-year term, and is governed by the 2023 Inducement Plan and individual option agreements.

Stoke Therapeutics (NASDAQ: STOK) announced on October 6, 2025 that Ian F. Smith has been appointed Chief Executive Officer after serving as Interim CEO since March 2025 and as a board member and advisor since 2023. Arthur Tzianabos resumes as Chairman. The company noted the start of its pivotal Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and a February 2025 collaboration with Biogen that gives Stoke U.S., Canada, and Mexico rights while Biogen holds rest-of-world rights. Stoke also began a second clinical program in Autosomal Dominant Optic Atrophy.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has granted 135,300 stock options to five new employees as inducement awards. The options were granted at an exercise price of $23.40 per share, matching the company's closing stock price on September 15, 2025.

The options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. These 10-year options were granted under the company's 2023 Inducement Plan as employment incentives in accordance with Nasdaq Listing Rule 5635(c)(4).